Logo image of PALI

PALISADE BIO INC (PALI) Stock Fundamental Analysis

NASDAQ:PALI - Nasdaq - US6963894026 - Common Stock - Currency: USD

0.742  +0.05 (+7.96%)

After market: 0.749 +0.01 (+0.94%)

Fundamental Rating

2

Taking everything into account, PALI scores 2 out of 10 in our fundamental rating. PALI was compared to 560 industry peers in the Biotechnology industry. While PALI seems to be doing ok healthwise, there are quite some concerns on its profitability. PALI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PALI has reported negative net income.
PALI had a negative operating cash flow in the past year.
PALI had negative earnings in each of the past 5 years.
In the past 5 years PALI always reported negative operating cash flow.
PALI Yearly Net Income VS EBIT VS OCF VS FCFPALI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

PALI's Return On Assets of -132.70% is on the low side compared to the rest of the industry. PALI is outperformed by 83.39% of its industry peers.
PALI's Return On Equity of -192.71% is on the low side compared to the rest of the industry. PALI is outperformed by 67.50% of its industry peers.
Industry RankSector Rank
ROA -132.7%
ROE -192.71%
ROIC N/A
ROA(3y)-103.57%
ROA(5y)-129.62%
ROE(3y)-138.57%
ROE(5y)-188.72%
ROIC(3y)N/A
ROIC(5y)N/A
PALI Yearly ROA, ROE, ROICPALI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PALI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PALI Yearly Profit, Operating, Gross MarginsPALI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50K -100K -150K -200K

More info and screens

5

2. Health

2.1 Basic Checks

PALI does not have a ROIC to compare to the WACC, probably because it is not profitable.
PALI has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PALI has more shares outstanding
PALI has a better debt/assets ratio than last year.
PALI Yearly Shares OutstandingPALI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
PALI Yearly Total Debt VS Total AssetsPALI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -20.57, we must say that PALI is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -20.57, PALI is doing worse than 85.54% of the companies in the same industry.
PALI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -20.57
ROIC/WACCN/A
WACC9.42%
PALI Yearly LT Debt VS Equity VS FCFPALI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

A Current Ratio of 3.24 indicates that PALI has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.24, PALI is doing worse than 63.21% of the companies in the same industry.
PALI has a Quick Ratio of 3.24. This indicates that PALI is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of PALI (3.24) is worse than 61.07% of its industry peers.
Industry RankSector Rank
Current Ratio 3.24
Quick Ratio 3.24
PALI Yearly Current Assets VS Current LiabilitesPALI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 70.08% over the past year.
PALI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)70.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.76%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, PALI will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.71% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y84.27%
EPS Next 2Y38.17%
EPS Next 3Y24.07%
EPS Next 5Y13.71%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PALI Yearly Revenue VS EstimatesPALI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2023 2030 2031 2032 50M 100M 150M 200M
PALI Yearly EPS VS EstimatesPALI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -100K -200K -300K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PALI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PALI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PALI Price Earnings VS Forward Price EarningsPALI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PALI Per share dataPALI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

PALI's earnings are expected to grow with 24.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.17%
EPS Next 3Y24.07%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PALI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PALISADE BIO INC

NASDAQ:PALI (5/30/2025, 8:25:06 PM)

After market: 0.749 +0.01 (+0.94%)

0.742

+0.05 (+7.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-11 2025-08-11
Inst Owners7.52%
Inst Owner Change30.8%
Ins Owners0.8%
Ins Owner Change0%
Market Cap3.56M
Analysts84.44
Price Target10.88 (1366.31%)
Short Float %0.94%
Short Ratio0.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.91%
Min EPS beat(2)23.66%
Max EPS beat(2)32.15%
EPS beat(4)3
Avg EPS beat(4)12.73%
Min EPS beat(4)-11.13%
Max EPS beat(4)32.15%
EPS beat(8)4
Avg EPS beat(8)3.92%
EPS beat(12)8
Avg EPS beat(12)37.63%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-64.83%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)52.34%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.48
P/tB 0.48
EV/EBITDA N/A
EPS(TTM)-7.66
EYN/A
EPS(NY)-1.07
Fwd EYN/A
FCF(TTM)-2.54
FCFYN/A
OCF(TTM)-2.54
OCFYN/A
SpS0
BVpS1.56
TBVpS1.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -132.7%
ROE -192.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-103.57%
ROA(5y)-129.62%
ROE(3y)-138.57%
ROE(5y)-188.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.24
Quick Ratio 3.24
Altman-Z -20.57
F-Score2
WACC9.42%
ROIC/WACCN/A
Cap/Depr(3y)144.44%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.76%
EPS Next Y84.27%
EPS Next 2Y38.17%
EPS Next 3Y24.07%
EPS Next 5Y13.71%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-15.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-9.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-9.52%
OCF growth 3YN/A
OCF growth 5YN/A